Patents Assigned to Chiesi Farmaceutici S.p.A.
-
Patent number: 11607389Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.Type: GrantFiled: May 12, 2022Date of Patent: March 21, 2023Assignee: Chiesi Farmaceutici S.p.A.Inventors: Bernard Charles Sherman, Michael Spino
-
Patent number: 11590074Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.Type: GrantFiled: September 14, 2020Date of Patent: February 28, 2023Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
-
Patent number: 11578068Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: December 12, 2018Date of Patent: February 14, 2023Assignee: Chiesi Farmaceutici S.p.A.Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Elizabeth Anne Skidmore
-
Publication number: 20220395454Abstract: The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.Type: ApplicationFiled: December 2, 2019Publication date: December 15, 2022Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Enrico ZAMBELLI, Sauro BONELLI, Diego COPELLI, Massimiliano DAGLI ALBERI, Francesca USBERTI
-
Patent number: 11524131Abstract: A device (100) for facilitating the positioning of a catheter for the administration of a liquid medicament to a spontaneously breathing patient. The method and system according to preferred embodiments of the present invention allows optimizing the dispensing said medicaments. In particular the system according to a preferred embodiment of the present invention allows the administration of an exogenous pulmonary surfactant to preterm patients.Type: GrantFiled: October 11, 2017Date of Patent: December 13, 2022Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Raffaele Dellaca, Ilaria Milesi
-
Patent number: 11510934Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.Type: GrantFiled: July 14, 2020Date of Patent: November 29, 2022Assignee: Chiesi Farmaceutici S.p.A.Inventors: Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
-
Publication number: 20220348545Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: May 6, 2022Publication date: November 3, 2022Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio LUTERO, Emanuele FERRARI, Fausto PIVETTI, Rocco BUSSOLATI, Edoardo MARIANI, Orsola VECCHI, Erhard BAPPERT, Caterina VENTRICI
-
Publication number: 20220313671Abstract: The present invention relates to methods for lowering stroke damages and/or lowering blood pressure in a subject with a stroke in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound, preferably clevidipine or a pharmaceutically acceptable salt or ester thereof. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.Type: ApplicationFiled: April 13, 2022Publication date: October 6, 2022Applicant: Chiesi Farmaceutici S.p.A.Inventor: Gregory Charles WILLIAMS
-
Patent number: 11458103Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.Type: GrantFiled: December 13, 2019Date of Patent: October 4, 2022Assignee: Chiesi Farmaceutici S.p.A.Inventors: Bernard Charles Sherman, Michael Spino
-
Patent number: 11426538Abstract: An actuator for a pressurized metered dose inhaler providing a significant reduction in the non-respirable coarse fraction of the emitted aerosol medicament impacting in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient, due to the fact that the mouthpiece portion has a central rounded opening of a well-defined width and distance from the nozzle aperture and also provided with a cylindrical recess, whose central axis is aligned with the central longitudinal axis of the mouthpiece portion and with the central longitudinal axis of the nozzle channel.Type: GrantFiled: March 31, 2017Date of Patent: August 30, 2022Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Diego Copelli, Andrea Casazza
-
Patent number: 11389401Abstract: Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.Type: GrantFiled: October 16, 2018Date of Patent: July 19, 2022Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
-
Publication number: 20220218678Abstract: The present invention relates to the use of agents, which are 1-phenyl-2-pyridinyl alkyl alcohol derivatives, for the prevention and/or treatment of cystic fibrosis in a subject, wherein the subject is characterized by at least one mutation in the gene encoding the CFTR protein, wherein the at least one mutation is causative for incorrect folding and/or processing of the CFTR protein. By the use of the compound according to the present invention, cystic fibrosis in the subject may be prevented or treated. The agent to be used according to the present invention has the capacity to restore the presence of the mutant CFTR protein at the cell surface, and thus act as CFTR correctors. The agent to be used according to the present invention may be administered to a subject in need thereof alone or in combination therapy with other agents, and is suitably administered by inhalation.Type: ApplicationFiled: March 31, 2022Publication date: July 14, 2022Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Gino VILLETTI, Serena BERTOLINI, Claudio SORIO
-
Patent number: 11369733Abstract: System comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, wherein the package is suitable and intended for receiving the replacement cap.Type: GrantFiled: March 11, 2020Date of Patent: June 28, 2022Assignee: Chiesi Farmaceutici S.p.A.Inventors: Jurgen Pfrang, Andreas Gorshofer, Marta Lombardini
-
Patent number: 11357731Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.Type: GrantFiled: April 3, 2020Date of Patent: June 14, 2022Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Bernard Charles Sherman, Michael Spino
-
Publication number: 20220175784Abstract: The invention relates to compounds of formula (I) inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them and therapeutic use thereof in the treatment of disorders associated with PI3K enzymes.Type: ApplicationFiled: March 24, 2020Publication date: June 9, 2022Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Matteo BIAGETTI, Paolo RONCHI, Claudio FIORELLI, Paolo BRUNO
-
Patent number: 11351187Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.Type: GrantFiled: August 2, 2016Date of Patent: June 7, 2022Assignee: Chiesi Farmaceutici S.p.A.Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
-
Patent number: 11352327Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: July 21, 2020Date of Patent: June 7, 2022Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Patent number: 11351299Abstract: System comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, wherein the package is suitable and intended for receiving the replacement cap.Type: GrantFiled: March 15, 2019Date of Patent: June 7, 2022Assignee: Chiesi Farmaceutici S.p.A.Inventors: Jurgen Pfrang, Andreas Gorshofer, Marta Lombardini
-
Patent number: 11332468Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: December 14, 2018Date of Patent: May 17, 2022Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Andrea Nuzzi
-
Patent number: 11311691Abstract: A device (100) for facilitating the positioning of a catheter for the delivery of liquid medicament to spontaneously breathing patient, including: —an elongated main body (101) shaped to follow the internal shape of the patient's upper airways, the elongated main body (101) being provided with guiding means (107) adapted to house a catheter; —a substantially ring-shaped terminal element (103) adapted to engage the internal wall of the patient's retro-pharynx, the substantially ring-shaped terminal element (103) being connected to the elongated main body (101) by means of at least one spoke (105), the substantially ring-shaped element (103) and the at least one spoke (105) creating a chamber where the medicament can be delivered through the catheter.Type: GrantFiled: April 28, 2015Date of Patent: April 26, 2022Assignee: CHIESI FARMACEUTICI S.p.AInventors: Raffaele Dellaca, Ilaria Milesi, Emanuela Zannin